ABSTRACT. The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, we report preliminary structure-activity relationship studies of a previously disclosed non-acidic sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylate function. The preferred compounds showed full agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of these non-carboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice resulted in significantly increased insulin sensitivity and a moderate but significant reduction in bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking FFA4.
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INTRODUCTION
The free fatty acid receptor 4 (FFA4, also known as GPR120) has in recent years appeared as a new potential target for the treatment of metabolic diseases. [1] [2] [3] [4] [5] [6] [7] The receptor was proposed as a possible antidiabetic and antiobesity target for the first time in 2005 when it was reported to be expressed in the intestinal tract and activated by dietary free fatty acids to stimulate incretin secretion, 8 although this property of the receptor remains controversial. 9 FFA4 was subsequently found also to be expressed in macrophages, liver and adipose tissue, and to mediate antiinflammatory and insulin sensitizing effects. 10 The report that mice lacking FFA4 develop obesity, insulin intolerance and fatty liver when fed a high-fat diet and that a human population with a dysfunctional FFA4 variant has an increased risk of obesity supported a significant role of the receptor in metabolic diseases. 11 Further support for this was recently provided by the finding that the selective FFA4 agonist Cpd A (Chart 1) increased insulin sensitivity and reduced inflammation and hepatic steatosis in mice fed a high-fat diet. 12 Moreover, FFA4 is implicated in regulation of glucagon, ghrelin and somatostatin release, representing likely contributing mechanisms of the observed metabolic phenotype. [13] [14] [15] [16] Chart 1. Representative FFA4 agonists
Although unsaturated and, in particular, omega-3 fatty acids were highlighted in the initial publications, 8, 10 it has become clear that FFA4 is activated by long-chain fatty acids with a profile that overlaps extensively with those that activate the more established antidiabetic target phthalimide 12 and for the acyclic sulfonamides 13 and 14. Acyclic sulfonamides, including 15-19, were synthesized similarly from the corresponding sulfonyl chlorides and anilines. 
RESULTS AND DISCUSSION
The compounds were screened on human (h) FFA4 in a β-arrestin-2 recruitment assay and compounds of particular interest were further tested in a Ca 2+ mobilization assay and on hFFA1. 18 The sultam 7, disclosed as an FFA4 agonist with pEC 50 of 6.74 in the Banyu patent, 21 showed somewhat lower activity in our assays with a pEC 50 of 6.36 in the β-arrestin-2 assay and 6.52 in the Ca 2+ assay (Table 1) . Notably, the compound did not show any activity on FFA1 at concentrations up to 100 µM. The FFA1 agonist 10 23 was found to also act as a full FFA4
agonist (see the Supporting Information), 18 and has been used herein as a reference compound. 24 This observation was initially surprising in light of the distinctly different structure and the lack of any acidic group.
Compound 7 was also affected by other mutations that impact the activity of 1 and α-linolenic acid, strongly suggesting that 7 also binds to the orthosteric site (Table S1) . 24 To probe the importance of the sulfonamide moiety, phthalimide 12, also exemplified in the Banyu patent but without activity data, 21 was produced and found to have 10-fold lower activity than 7 and low partial efficacy, indicating that the sulfonamide is important for agonist activity but that replacement by other hydrogen bond acceptors is possible. The acyclic sulfonamide 13, containing a weakly acidic group (calculated pK a 7.7) 25 exhibited further reduced activity.
Interestingly, N-methylation to give the non-acidic ring-opened analogue 14 resulted in complete loss of activity, possibly reflecting that planarity between the aromatic ring and the S-N bond is a requirement. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 26 Related to 13, the sulfonamide DC260126 (15) has been described as an FFA1 antagonist and was, somewhat surprisingly, reported to improve insulin sensitivity and β-cell function in rats and db/db mice. 27, 28 We confirmed its FFA1 antagonist activity (pIC 50 = 5.09) but found that the compound also acts as an FFA4 agonist in the β-arrestin-2 recruitment assay although it was devoid of activity in the Ca 2+ assay ( Explorations of the western part of the structure suggested that the benzosultam system was favored. Turning attention back to the eastern site, the eastern phenyl ring of 8 was scanned with the non-polar methyl substituent (26, 27, 28) and the polar cyano (29) (30) (31) and meta-cyanomethyl (32) substituents, in all cases these resulted in decreased potency with para-substituents being somewhat better tolerated (Table 3) . 
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Further investigation of 8 revealed antagonistic activity on FFA1, but without the ability to completely block the agonist response (i.e. "partial antagonism", Table 1 ). A similar effect was seen with all substituted analogues exhibiting noticeable agonistic activity (EC 50 <10 µM) on FFA4. These results are surprising because they indicate that this compound series also has the ability to interact with and modulate FFA1 despite its structural dissimilarity from other FFA1
agonists and the absence of an acidic functional group. However, the inability of the compounds to completely block activity of 10 suggests non-competitive binding and allosteric interaction with FFA1.
In contrast to the phenoxy compounds, the pyridines 7, 33, 13, 14 did not show any sign of agonistic or antagonistic activity on FFA1. These structures were therefore explored further by altering the attachment point at the pyridine. Thus, the 4-pyridyl (33) derivative resulted in a 3-fold reduced potency, whereas the 2-pyridyl (34) gratifyingly showed a 3.5-fold increased potency to achieve an EC 50 of 128 nM.
Finally, the importance of the meta-fluoro substituent at the central ring of 34 was assessed.
Removal of the fluoro substituent in 36 resulted in a 10-fold reduced potency and indicated, Overall, 34 and 38 stood out as the most potent FFA4 agonists in both the β-arrestin-2 and the Ca 2+ assays with essentially equal activity in the former. Although 38 appeared more potent in the Ca 2+ assay, the compound showed only partial agonist activity, whereas 34 was a full agonist in both assays as well as less lipophilic (∆ClogP ~0.5). Compound 34 showed no activity at the other free fatty acid receptors FFA1, FFA2 or FFA3 at up to 30 µM, indicating >300-fold selectivity. Experimental log D 7.4 measurements showed identical lipophilicity for 34 and 7 (3.17 and 3.12, respectively). Solubility studies for compounds 7, 34 and 38 in PBS indicated progressively lower solubility with 38 being virtually insoluble (11, 1.3 and 0.1 µM, respectively), however, the solubility of the two latter in fasting state simulated intestinal fluid (FaSSIF) gave a somewhat better picture for 34 (14 µM for 34 and 0.9 µM for 38). Thus, 34 was selected for in vivo studies. The low solubility of the compound did not cause any problems in relation to these. Prior to the mouse studies, the activity and specificity of 34 and the two other most potent and selective agonists, 7 and 38, on the mFFA4 and mFFA1 were investigated.
Completely preserved activity was confirmed for all three compounds in the Gq-dependent Ca 2+ mobilization assay on mFFA4 (pEC 50 = 7.08 ± 0.05, 6.83 ± 0.08 and 7.14 ± 0.08 for 7, 34 and 38, respectively), with no activity detected up to 100 µM on mFFA1. Further, 34 was also tested in the β-arrestin assay, confirming full agonistic activity with pEC 50 = 6.32 ± 0.06, again with no sign of activity on mFFA1. Compound 34 also failed to induce a response when tested on the FFA4 has been reported to mediate free fatty acid promoted incretin release and to improve glucose tolerance, 8, 12 and mice lacking FFA4 show impaired glucose homeostasis, an effect believed to involve improper regulation of glucagon secretion. 14 Thus, the effect of 34 as well as 7 in a glucose tolerance test was investigated by oral dosing prior to an oral glucose challenge.
This resulted in significant lowering of plasma glucose levels for both compounds compared to vehicle ( Figure 2 ). FFA4 has attracted high interest as a potential antidiabetic target in particular because of results indicating that the receptor mediates insulin sensitization, anti-inflammatory effects, protection of pancreatic islets, and that it may even counteract obesity. [3] [4] [5] [6] 10, 11, 29 However, each of these is difficult to assess satisfactorily in acute treatment studies. To evaluate the effects of 34 on some of these, a chronic treatment study in DIO mice was performed with daily dosing of 10 mg/kg 34 over a three week period. Mice lacking FFA4 were included to assess and confirm receptor specific activity of the ligand. The wild-type mice were littermates of the FFA4(-/-) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 animals. As observed in normal mice, a glucose challenge 15 min after dosing in DIO mice on the first day significantly reduced plasma glucose levels in 34-treated wild-type mice compared to vehicle-treated wild-type mice, whereas 34 had no effect on glucose levels in the FFA4(-/-) animals ( Figure 3, top) . The effect was significant in the wild-type animals also when calculated relative to t = -30 min (see the Supporting Information). A significantly increased insulin level was observed 30 min after challenge for the wild-type mice treated with 34 relative to vehicle treated wild-type mice, whereas the difference was absent in mice lacking FFA4 (Figure 3 , bottom). This confirms that the effect of 34 on glucose excursion when dosed 15 minutes before the challenge is mediated by FFA4. Studies to investigate the mechanism of this effect are in progress. After treatment over 21 days, the fasting insulin levels of the 34 treated wild-type DIO mice was significantly reduced compared to vehicle treated mice, whereas no difference was observed between the FFA4(-/-) groups (Figure 4 , top). These results indicate that 34 promotes insulin sensitization in mice through activation of FFA4. An oral glucose tolerance test on day 21
( Figure 4 , bottom) showed an even more robust effect than on day 0, presumably an effect of increased insulin sensitization. bodyweight in the wild-type mice of 3-4 grams (7-9%) towards the end of the study, whereas no effect, or even a weak trend towards weight gain, was observed in the FFA4(-/-) animals ( Figure   5 ). These results support the notion that FFA4 may represent a potential anti-obesity target, an effect that would be an important add-on to regulation of glucose homeostasis in an antidiabetic drug. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 CONCLUSION Most currently known FFA4 agonists are carboxylic acids assumed to mimic the endogenous free fatty acid agonists. Most of these also exhibit some degree of activity on FFA1. In the search for highly selective FFA4 agonists, we investigated a non-acidic benzosultam ligand known from the patent literature and conducted a preliminary structure-activity relationship study around this scaffold. Interestingly, mutagenesis studies indicated that these compounds also bind to the same site as α-linolenic acid and 1 and also require carboxylate interaction partner Arg99 2.64 for activity despite the absence of a carboxylate. Given the limited overall homology between FFA1
and FFA4, even though they are both activated by overlapping sets of medium-and long-chain free fatty acids, it was surprising that a sub-series of these compounds also interacted with FFA1
to produce partial blockade of this receptor. Compound 34, a full FFA4 agonist with comparable potency in both Ca 2+ -and β-arrestin-2-based assays, showed complete selectivity over FFA1 and other free fatty acid receptors. Its distinctly different structure from the carboxylic acid FFA4
agonists currently used as tool compounds makes 34 a suitable orthogonal tool in combination with these for further studies of the function of FFA4. The compound was investigated in vivo and was found to lower plasma glucose levels after an oral glucose challenge when dosed orally 15 minutes prior to the challenge, an effect that was confirmed to be mediated by FFA4 as this was not observed in animals lacking FFA4. Furthermore, 34 robustly increased insulin sensitivity after chronic dosing in DIO mice and led to moderately reduced bodyweight over the course of the study, despite no significant effects on food or water intake. Altogether, 34 is a non-acidic 
EXPERIMENTAL SECTION

Synthesis
Commercial starting materials and solvents were used without further purification. THF was freshly distilled from sodium/benzophenone. Water was filtered and demineralized (Milli-Q). 
2-(3-Phenoxyphenyl)isothiazolidine 1,1-dioxide (24).
Step 1: To a solution of 3-phenoxyaniline (501 mg, 2.71 mmol) in dry CH 2 Cl 2 (10 mL) was added pyridine (0.57 mL, 7.02 mmol) and 3-chloropropanesulfonyl chloride (0.4 mL, 3.24 mmol) at room temperature. The reaction was stirred for 16 h, then diluted with CH 2 Cl 2 and washed successively with HCl (1N, aq) and NaHCO 3 (sat. aq.), dried (Na 2 SO 4 ) and concentrated to give 3-chloro-N-(3-phenoxyphenyl)propane-1-sulfonamide as a crude yellow oil that was used directly in the next step.
Step 2: To a solution of 3-chloro-N-(3-phenoxyphenyl)propane-1-sulfonamide in DMF (15 mL) was added K 2 CO 3 (963 mg, 6.97 mmol) and stirred at 50 °C for 16 h. The reaction mixture was cooled to room temperature, diluted with water and extracted with EtOAc (3x). The combined organic phases were washed with water and brine, dried (Na 2 SO 4 ) and concentrated.
The crude was purified by flash chromatography (EtOAc:PE, 1:1) to give 24 as a pale yellow oil which solidified to an off-white solid after a week under high vacuum (596 mg, 72% over two The spectra is in accordance with the literature. 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Fluoro-5-(pyridin-4-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (33) .
2-(3-Fluoro-5-(p-tolyloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (28
3-(3-(1,1-Dioxidobenzo[d]isothiazol-2(3H)-yl)-5-fluorophenoxy)benzonitrile (30)
.
2-(3-
The title compound was obtained as described for 22 using 25 (79 mg, 0.28 mmol) and 4-bromopyridine hydrochloride (46 mg, 0.22 mmol) as starting materials. The crude product was purified by flash chromatography (EtOAc/PE, 9:1) to provide 33 as a white solid (34 mg, 40%). min, 98.8%.
2-(3-Fluoro-5-(pyridin-2-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (34).
The title compound was obtained as described for 22 using 25 (75 mg, 0.27 mmol) and 2-iodopyridine (24 µL, 0.22 mmol) as starting materials. The crude product was purified by flash chromatography (EtOAc/PE, 2:3) and the title compound 34 was recrystallized from acetone/PE as a white solid (36 mg, 45%). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
2-(3-Iodophenoxy)pyridine (35).
A vial was charged with 3-iodophenol (500 mg, 2.27 mmol), K 2 CO 3 (345 mg, 2.5 mmol), dry DMF (2 mL) and 2-fluoropyridine (196 µL, 2.27 mmol). The vial was capped and heated at 140 ºC under microwave irradiation for 6 h. The reaction was partitioned between water and EtOAc, the aqueous phase was extracted with EtOAc (2x). The combined organic phases were washed with brine, dried (Na 2 SO 4 ) and concentrated.
The crude product was purified by flash chromatography (EtOAc/PE, 1:9) to give 35 as colorless oil that solidified upon standing (416 mg, 62% 
2-(3-Chloro-5-(pyridin-2-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide (38).
The title compound was obtained as described for 21 using 20 (37 mg force field. 35 Ligands were prepared using Lig-Prep. 36 Ionization states were generated using Epik at pH 7.0 ±1.0, and low energy ring conformations were restricted to one per ligand.
Induced-fit docking studies were performed using the extended sampling protocol as implemented in Schrodinger suite 2015-3. 37 Ligand conformational sampling was performed using default settings. Prime was used to refine residues within 5.0 Å of ligand poses. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 the appropriate ligands to be tested for antagonism. Upon addition of 300 nM 10, Fura2 fluorescent emission and subsequent Ca 2+ responses were measured as described above. responses were then measured as described above.
Data Analysis. BRET and Ca 2+ data is presented as the means ± S.E. of 2-4 independent experiments, with all data analysis and curve fitting carried out using three parameter sigmoidal concentration-response curves generated from the GraphPad Prism software package version 5.0b (GraphPad, San Diego).
Animal studies
Male wild-type mice were obtained from Charles Rivers (Maidstone, Kent, UK). Mice were received at five weeks of age. FFA4 (Taconic) knockout mice on a C57Bl6 background were maintained in house and were over more than 8 generations crossed to the Bl6 background. They were fed on standard laboratory chow (Beekay Feed; B&K Universal Ltd., Hull, UK) until used, except that for the studies on diet-induced obesity when FFA4(-/-) mice and wild-type littermates were fed from the age of 6 weeks on a high-fat (63% by energy; Open Source D12492, Research 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Diets, New Brunswick, NJ, USA) for 5 months. The bodyweights of the genotypes at the onset of dosing (day 0) were 47.1 ± 3.1 g for wild-type mice and 46.0 ± 3.8 g the FFA4(-/-) mice.
Housing and procedures were conducted in accordance with the UK Government Animal Oral glucose tolerance. Oral glucose tolerance was measured as described previously. 39 Briefly, mice were fasted for five h before being dosed with glucose (3 g/kg bodyweight, po).
Blood samples (10 µL) were taken from the tip of the tail after applying a local anesthetic (Lignocaine™; Centaur Services, UK), 30 min and immediately before, and 30, 60, 90, 120 and 180 min after dosing the glucose load. Whole blood was mixed with hemolysis reagent and blood glucose was measured in duplicate using the Sigma Enzymatic (Glucose Oxidase Trinder;
ThermoFisher Microgenics, UK) colorimetric method and a SpectraMax 250 (Molecular Devices Corporation, Sunnyvale, CA, USA).
Insulin. Plasma insulin levels were measured using a murine insulin ELISA kit (CrystalChem, USA) according to the manufacturer's recommendation. Whole blood was collected into EDTA tubes and spun at 3,000 g for 5 min at 4 °C and the plasma stored at −80 °C prior to analysis.
Plasma samples were assayed in duplicate and the absorbance of both unknowns and standards measured using the Spectromax at 450 nm. Present Addresses †If an author's address is different than the one given in the affiliation line, this information may be included here.
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